Προβληματισμοι στην χρηση αντιαιμοπεταλιακων στα οξέα ισχαιμικά σύνδρομα

Similar documents
Optimal lenght of DAPT in different clinical scenarios

Changing Course: Anticoagulation in Secondary Prevention of Cardiovascular Disease Events

Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease

When and how to combine antiplatelet agents and anticoagulant?

Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients

Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)

Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?

Which drug do you prefer for stable CAD? - P2Y12 inhibitor

Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!

Razionale ed evidenze scientifiche di Doppia Antiaggregazione Piastrinica a lungo termine nel Paziente con Sindrome Coronarica Acuta

Stable CAD, Elective Stenting and AFib

Disclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None

Quoi de neuf en cardio-gériatrie? Pr Olivier Hanon Hôpital Broca, Paris

Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά

Disclosure Slide. Controversies in Anticoagulation. Presenter Disclosure Information. Challenges in Anticoagulation

Στεφανιαίος ασθενής με μη βαλβιδική Κολπική Μαρμαρυγή - Νέες στρατηγικές

Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management

Is there enough evidence for DAPT after endovascular intervention for PAOD?

ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium

NAVIGATING THROMBOSIS AND BLEEDING AT THE INTERSECTION OF ATRIAL FIBRILLATION AND CORONARY STENTING

DECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.

Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland

Dual Antiplatelet duration in ACS: too long or too short?

GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017

TRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust

Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center

PCI in Patients with AF Optimizing Oral Anticoagulation Regimen

Διαχείριση των Οξέων Στεφανιαίων Συνδρόμων: Ο ρόλος των αντιαιμοπεταλιακών και η βέλτιστη διάρκεια της διπλής αντιαιμοπεταλιακής αγωγής

Belinda Green, Cardiologist, SDHB, 2016

A new era in the treatment of peripheral artery disease (PAD)?

Triple Therapy: A review of the evidence in acute coronary syndrome. Stephanie Kling, PharmD, BCPS Sanford Health

Dual Antiplatelet Therapy Made Practical

The Great debate: thrombocardiology post-compass

Optimal Duration and Dose of Antiplatelet Therapy after PCI

FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS

Κωνσταντίνος Π. Τούτουζας Επ. Καθηγηηής Καρδιολογίας. A Πανεπιζηημιακή Καρδιολογική Κλινική, Ιπποκράηειο Νοζοκομείο

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

Does COMPASS Change Practice?

Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials

Asif Serajian DO FACC FSCAI

How Long Patietns Will Be on Dual Antiplatelet Therapy?

7 th Munich Vascular Conference

Αντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο)

UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES

Robert C. Welsh, MD, FRCPC Professor of Medicine, University of Alberta Zone Clinical Department Head, Cardiac Sciences

Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor

Antithrombotic therapy in the ACS patient with atrial fibrillation

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial

Updated and Guideline Based Treatment of Patients with STEMI

ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ. Εξατοµικευµένη αντιαιµοπεταλιακή αγωγή. Ποιο είναι το µέλλον?

State of the Art in the ACS Atrial Fibrillation Overlap Syndrome

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

Dr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου

Antiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology

SCA ST- : recommandations européennes 2015 La durée de la bithérapie : à géométrie variable?

P2Y 12 blockade. To load or not to load before the cath lab?

Special Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원

The Korean Society of Cardiology COI Disclosure

Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015

The Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke

P 2 Y 12 Receptor Inhibitors

Clopidogrel has been evaluated in clinical trials that included cardiovascular patients

10 Steps to Managing Non-ST Elevation ACS

Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network

News Release. For UK Media

תרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון מרכז רפואי רבין

ACCP Cardiology PRN Journal Club

New antiplatelets in NSTEMI. Overview: dual anti-platelet oral therapy

3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.

Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.

Lo studio Pegasus: il ruolo di Ticagrelor dopo i primi 12 mesi di trattamento. C. Cavallini Perugia

Clopidogrel Use in ACS and PCI: Clinical Trial Update

Antithrombotic Therapy for Long-Term Secondary Prevention Considerations for Long-Term DAPT

Learning Objectives. Epidemiology of Acute Coronary Syndrome

Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017

New insights in stent thrombosis: Platelet function monitoring. Franz-Josef Neumann Herz-Zentrum Bad Krozingen

8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes

Controversies in Cardiac Pharmacology

'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome'

The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease

Anti-platelet therapies and dual inhibition in practice

Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary

Adjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013

Antiplatelet in diabetics: strong but incomplete umbrella

1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES

Improving Patient Outcomes: Updated Treatment Strategies in the Management of Acute Coronary Syndrome

Re- Setting our COMPASS for Secondary Prevention in Atherosclerotic Vascular Disease

Columbia University Medical Center Cardiovascular Research Foundation

DOUBLE or TRIPLE ANTI-TROMBOTIC THERAPY in ACS. Maarten L Simoons Thoraxcenter - Erasmus MC Rotterdam - The Netherlands

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University

New Study Presented at American Heart Association (AHA) Scientific Sessions 2016:

Optimal Duration of Dual Anti- Platelet Therapy. December 19, 2015

Study design: multicenter, randomized, open-label trial following a PROBE design

Antiplatelet Therapy: Current Recommendations for Choice of Agent and Concurrent Therapy with Warfarin and Novel Oral Anticoagulants

ΔΟΡΥΦΟΡΙΚΟ ΣΥΜΠΟΣΙΟ. Αντιπηκτική αγωγή στη σύγχρονη κλινική πράξη το 2017

Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC

ΔΙΑΧΕΙΡΙΣΗ ΑΣΘΕΝΩΝ ΜΕ ΣΤΕΦΑΝΙΑΙΑ ΚΑΡΔΙΟΠΑΘΕΙΑ ΚΑΙ ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ:ΚΙΝΔΥΝΟΙ ΚΑΙ ΟΦΕΛΗ ΔΙΠΛΗΣ ΚΑΙ ΤΡΙΠΛΗΣ ΘΕΡΑΠΕΙΑΣ

INNOVATIONS 2017: Acute Coronary Syndrome Antiplatelet Therapies in Medical and Invasive Strategies.

La terapia antiaggregante nel paziente con stroke

Is Cangrelor hype or hope in STEMI primary PCI?

Transcription:

Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΚΑΙ ΟΜΩΝΥΜΟ ΕΡΓΑΣΤΗΡΙΟ ΙΑΤΡΙΚΗ ΣΧΟΛΗ ΠΑΝΕΠΙΣΤΗΜΙΟΥ ΑΘΗΝΩΝ ΙΠΠΟΚΡΑΤΕΙΟ ΓΕΝΙΚΟ ΝΟΣΟΚΟΜΕΙΟ ΑΘΗΝΩΝ Διευθυντής: Καθηγητής ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Προβληματισμοι στην χρηση αντιαιμοπεταλιακων στα οξέα ισχαιμικά σύνδρομα Δημήτριος Τούσουλης Καθηγητης Καρδιολογίας Α Πανεπιστημιακή Καρδιολογική Κλινική Ιπποκράτειο Γ.Ν.Α.

Ho orarium from Me ari i, Phizer, MSD Via ex E pe, Bayer, Amje, Boerger I ge heim

ΘΕΡΑΠΕΙΑ

Αντιαιμοπεταλιακή αγωγη μετα απο ΟΣΣ χρειαζεται?

Aspirin after myocardial infarction ISIS-2 Trial Aspirin reduces CV death in the first 5 weeks post MI Lancet 1988

Aspirin after myocardial infarction BMJ 2011

Διπλη αντιαιμοπεταλιακή αγωγη μετα απο ΟΣΣ Ειναι αναγκαία?

DAPT in STEMI CLARITY-TIMI 28 STEMI receiving fibrinolysis clopidogrel 300 loading + 75 thereafter vs placebo Sabatine MS et al, NEJM 2005

Cumulative Hazard Rate DAPT in NSTEMI / ACS Primary End Point - MI/Stroke/CV Death 0.14 0.12 0.10 CURE Placebo + ASA* 11.4% 9.3% 0.08 0.06 Clopidogrel + ASA* 0.04 0.02 0.00 * In combination with standard therapy 0 3 6 9 12 Months of Follow-Up The CURE Trial Investigators. N Engl J Med. 2001;345:494-502. 20% RRR P < 0.001 N = 12,562

DAPT in STEMI / NSTEMI-ACS

Prasugrel in STEMI / non-ste ACS TRITON-TIMI 38 Efficacy and Safety endpoints Wiviott SD et al, NEJM 2007

Prasugrel in STEMI / non-ste ACS TRITON-TIMI 38 Safety endpoint: bleeding Wiviott SD et al, NEJM 2007

Cumulative incidence (%) Cumulative incidence (%) PLATO: primary efficacy endpoint over time (composite of CV death, MI or stroke) 8 6 4 Clopidogrel Ticagrelor 5.4 4.8 8 0-30 days 31-360 days 6 4 Clopidogrel Ticagrelor 6.6 5.3 2 2 0 (HR, 0.88; 95% CI, 0.77-1.00; P=0.045) 0 (HR, 0.80; 95% CI, 0.70-0.91; P<0.001) 0 10 20 30 Days after randomization No. at risk Ticagrelor 9333 8942 8827 8763 Clopidogrel 9291 8875 8763 8688 31 90 150 210 270 330 Days after randomization * 8673 8543 8397 7028 6480 4822 8688 8437 8286 6945 6379 4751 *Excludes patients with any primary event during the first 30 days Wallentin L, et al. N Engl J Med. 2009;361:1045-1057.

K-M estimated rate (% per year) PLATO: Time to major bleeding: primary safety endpoint* 15 10 Ticagrelor Clopidogrel 11.6% 11.2% P=NS 5 (HR 1.04; 95% CI, 0.95-1.13; P=0.43) 0 No. at risk 0 60 120 180 240 300 360 Days from first IP dose Ticagrelor 9235 7246 6826 6545 5129 3783 3433 Clopidogrel 9186 7305 6930 6670 5209 3841 3479 *Both groups included aspirin Wallentin L, et al. N Engl J Med. 2009;361:1045-1057.

Διπλη Αντιαιμοπεταλιακή αγωγη μετα απο stent

Prasugrel in STEMI / non-ste ACS TRITON-TIMI 38 Efficacy endpoints: stent thrombosis Wiviott SD et al, NEJM 2007

Ticagrelor in STEMI / non-ste ACS PLATO Trial Efficacy endpoints: stent thrombosis Wallentin L et al, NEJM 2009

Predictors of stent thrombosis Tada T et al. JACC: Cardiovasc Interv 2013;5:1267-74

Διπλη Αντιαιμοπεταλιακή αγωγη Διάρκεια<12 μηνες?

Mehran R et al. J Am Coll Cardio 2015;65:1103-6

Palmerini T et al. Eur Heart J 2017; e-pub ahead of print

An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention PIONEER AF-PCI

Patients With Atrial Fibrillation Undergoing Coronary Stent Placement: PIONEER AF-PCI End of treatment 12 months 2100 patients with NVAF Coronary stenting No prior stroke/tia, GI bleeding, Hb<10, CrCl<30 72 hours After Sheath removal R A N D O M I Z E 1,6, or 12 months Pre randomization MD Choice Rivaroxaban 2.5 mg bid Clopidogrel 75 mg qd Aspirin 75-100 mg qd 1,6, or 12 months Pre randomization MD Choice VKA (target INR 2.0-3.0) Clopidogrel 75 mg qd Aspirin 75-100 mg qd Rivaroxaban 15 mg qd* Clopidogrel 75 mg qd Rivaroxaban 15mg QD Aspirin 75-100 mg qd VKA (target INR 2.0-3.0) Aspirin 75-100 mg qd WOEST Like ATLAS Like Triple Therapy Primary endpoint: TIMI major + minor + bleeding requiring medical attention Secondary endpoint: CV death, MI, and stroke (Ischemic, Hemorrhagic, or Uncertain Origin) *Rivaroxaban dosed at 10 mg once daily in patients with CrCl of 30 to <50 ml/min. Alternative P2Y 12 inhibitors: 10 mg once-daily prasugrel or 90 mg twice-daily ticagrelor. Low-dose aspirin (75-100 mg/d). Open label VKA

Cardiovascular Death, Myocardial Infarction, or Stroke (%) Kaplan-Meier Estimates of First Occurrence of CV Death, MI or Stroke Riva + P2Y 12 6.5% 6.0% 5.6% Riva + DAPT VKA + DAPT Riva + P2Y 12 v. VKA + DAPT HR=1.08 (95% CI: 0.69-1.68) p=0.750 Riva + DAPT v. VKA + DAPT HR=0.93 (95% CI: 0.59-1.48) p=0.765 No. at risk Riva + P2Y 12 Riva + DAPT VKA + DAPT 694 704 695 648 662 635 633 640 607 621 628 579 Days Treatment-emergent period: period starting after the first study drug administration following randomization and ending 2 days after stop of study drug. Composite of adverse CV events is composite of CV death, MI, and stroke. Hazard ratios as compared to VKA group are based on the (stratified, only for the Overall, 2.5 mg BID/15 mg QD comparing VKA) Cox proportional hazards model. Log-Rank P-values as compared to the VKA group are based on the (stratified, only for Overall, 2.5 mg BID/115 mg QD comparing VKA) two-sided log rank test. 6 Subjects were excluded from all efficacy analyses because of violations in Good Clinical Practice guidelines 590 596 543 562 570 514 430 457 408

All Cause Rehospitalization (%) All Cause Hospitalization for an Adverse Event 41.5% VKA + DAPT Riva + P2Y 12 Riva + DAPT 34.1% 31.2% Riva + P2Y 12 v. VKA + DAPT HR=0.77 (95% CI: 0.65-0.92) p=0.005 ARR=7.4 NNT=14 Riva + DAPT v. VKA + DAPT HR=0.74 (95% CI: 0.61-0.88) p=0.001 ARR=10.3 NNT=10 No. at risk Riva + P2Y 12 Riva + DAPT VKA + DAPT 696 706 697 609 607 592 582 570 540 559 548 490 Days Treatment-emergent period: period starting after the first study drug administration following randomization and ending 2 days after stop of study drug. Rehospitalizations do not include the index event and include the first rehospitalization after the index event. Hazard ratios as compared to the VKA group are based on the Cox proportional hazards model. Log-Rank P-values as compared to VKA group are based on the two-sided log rank test. 496 493 422 437 454 369 322 367 272

Διπλη Αντιαιμοπεταλιακή αγωγη μετα απο ΟΣΣ >12 μηνες?

MI is the tip of the atherothrombotic iceberg ACUTE PLAQUE RUPTURE ACS (UA/NSTEMI/STEMI) ACS, acute coronary syndrome; NSTEMI, non-st segment elevation myocardial infarction; STEMI, ST segment elevation myocardial infarction; UA, unstable angina. Goldstein JA. J Am Coll Cardiol 2002;39:1464 1467.

Features of conculprit lesion vulnurability across the same artery Toutouzas K,.Tousoulis D, EHJ 2015

Platelets may be involved in all stages of atherothrombosis Initiation and progression Plaque rupture Acute thrombus formation Platelet adhesion & activation Release of inflammatory mediators, cell recruitment Platelet activation Release of inflammatory mediators, plaque instability Platelet aggregation Fuentes QE et al. Platelets 2013;24(4):255 262; Gawaz M. Eur Heart J Suppl 2008:10(Suppl 1);14 17.

Recurrent events are as likely to originate from a new atherosclerotic plaque as they are from the initial culprit lesion PROSPECT study: Prospective study of the natural history of atherosclerosis over 3 years in patients with ACS who underwent PCI (n=697)[stone 2011] All events 20.4% ACS, acute coronary syndrome; MACE, major adverse cardiac events; PCI, percutaneous coronary intervention; PROSPECT, Providing Regional Observations to Study Predictors of Events in the Coronary Tree. Stone GW et al. N Engl J Med 2011;364:226 235.

Impact of bleeding on prognosis Rao et al, JAMA 2004

CHARISMA Study MI subgroup Bhatt DL et al, J Am Coll Cardiol 2007;49:1982 8.

DAPT Study - Design

DAPT Study Primary safety end point

DAPT Study Endpoints

DAPT Study MI vs non-mi patients

DAPT Study MI All MIs No-stent thrombosis MIs

Event rate (%) PEGASUS-TIMI 54: Primary Endpoint 10 9 8 Placebo Ticagrelor 90 mg bid Ticagrelor 60 mg bid 9.04% Placebo 7.85% 90 mg bid 7 7.77% 60 mg bid 6 5 4 3 2 1 0 Ticagrelor 90 mg vs placebo HR 0.85 (95% CI 0.75 0.96) P=0.008 Ticagrelor 60 mg vs placebo HR 0.84 (95% CI 0.74 0.95) P=0.004 0 3 6 9 12 15 18 21 24 27 30 33 36 No. at risk Placebo 90 mg bid 60 mg bid 7067 7050 7045 6979 6973 6969 6892 6899 6905 6823 6827 6842 6761 6769 6784 P<0.026 indicates statistical significance; CI, confidence interval; HR, hazard ratio Months from randomisation 6681 6719 6733 6508 6550 6557 6236 6272 6270 5876 5921 5904 5157 5243 5222 4343 4401 4424 3360 3368 3392 2028 2038 2055 Bonaca MP et al. N Engl J Med 2015;372:1791 1800

PEGASUS-TIMI 54: Efficacy Endpoints Endpoint 3-year KM event rates (%) Ticagrelor Placebo HR (95% CI) P value Primary CV death, MI or stroke (1558 events) CV death (566 events) MI (898 events) Stroke (313 events) 7.85 9.04 0.85 (0.75 0.96) 0.008 7.77 9.04 0.84 (0.74 0.95) 0.004 7.81 9.04 0.84 (0.76 0.94) 0.001 2.94 3.39 0.87 (0.71 1.06) 0.15 2.86 3.39 0.83 (0.68 1.01) 0.07 2.90 3.39 0.85 (0.71 1.00) 0.06 4.40 5.25 0.81 (0.69 0.95) 0.01* 4.53 5.25 0.84 (0.72 0.98) 0.03* 4.47 5.25 0.83 (0.72 0.95) 0.005* 1.61 1.94 0.82 (0.63 1.07) 0.14* 1.47 1.94 0.75 (0.57 0.98) 0.03* 1.54 1.94 0.78 (0.62 0.98) 0.03* 0.4 0.6 0.8 1 1.25 1.67 Ticagrelor better Placebo better Ticagrelor 90 mg bid Ticagrelor 60 mg bid Ticagrelor pooled *Indicates nominal P value; P<0.026 indicates statistical significance Bonaca MP et al. N Engl J Med 2015;372:1791 1800

3-year KM event rate PEGASUS-TIMI 54: Bleeding 5 4 3 2 P<0.001 2.6 2.3 P<0.001 Ticagrelor 90 mg bid Ticagrelor 60 mg bid Placebo P=NS P=NS P=NS 1 0 1.1 TIMI major bleeding 1.3 1.2 0.4 TIMI minor bleeding 0.6 0.7 0.6 0.6 0.6 0.5 Fatal bleeding or ICH ICH 0.1 0.3 0.3 Fatal bleeding Rates are presented as 3-year Kaplan-Meier estimates Bonaca MP et al. N Engl J Med 2015;372:1791 1800

PEGASUS-TIMI 54: Numbers Needed to Treat and Numbers Needed to Harm (ITT Population) Efficacy endpoint Primary endpoint: CV death, MI or stroke Ticagrelor 90 mg bid Estimated risk difference NNT Ticagrelor 60 mg bid Estimated risk difference NNT 1.19% 85 1.27% 79 CV death 0.45% 221 0.53% 189 MI 0.85% 119 0.72% 139 Stroke 0.33% 304 0.47% 213 Safety endpoint Primary safety endpoint: TIMI major bleeding Estimated risk difference NNH Estimated risk difference NNH 1.22% 82 0.94% 107 ICH 0.08% 1309-0.01% -8005 Fatal bleeding -0.06% -1753-0.05% -2182 Estimated risk difference is the difference in 3-year Kaplan-Meier percent between ticagrelor and placebo based on intention-to-treat analyses NNH, number needed to harm; NNT, number needed to treat Data on file: ATLAS approval ID 773,116.011 59

Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials Major adverse cardiovascular events Udell JA et al. Eur Heart J. 2015;37(4):390-399.

Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials Efficacy & safety end points Udell JA et al. Eur Heart J. 2016;37(4):390-399.

Διπλη Αντιαιμοπεταλιακή αγωγη μετα απο ΟΣΣ >12 μηνες? Πιοος ο υποψηφιος?

Predictors of combined treatment effect Yeh RW et al. JAMA 2016;315:1735-49 63

Cumulative Incidence of ST/MI Continued Thienopyridine vs. Placebo DAPT Score <2 (Low); N=5731 Cumulative Incidence of GUSTO Moderate/ Severe Bleed Cumulative Incidence of MACCE 10 % 8 % 6 % 4 % 2 % 0 % 1 2 Continued Thienopyridine Placebo 1.7% vs. 2.3% P=0.07 1 5 1 8 GUSTO Moderate/ Severe Bleeding 2 1 Months After Enrollment 10 % 8 % 6 % 4 % 2 % 0 % 1 Yeh RW et al. JAMA 2016;315:1735-49 2 Stent Thrombosis or MI 2 4 2 7 3.0% vs. 1.4% P<0.001 3 0 Continued Thienopyridine Placebo 1 5 1 8 10 % 8 % 6 % 4 % 2 % 0 % 1 2 2 1 Months After Enrollment 2 4 Continued Thienopyridine Placebo 3.7% vs. 3.8% P=0.73 1 5 2 7 1 8 2 1 Months After Enrollment 3 0 MACCE 2 4 2 7 3 0 64

Cumulative Incidence of ST/MI Continued Thienopyridine vs. Placebo DAPT Score 2 (High); N=5917 Cumulative Incidence of GUSTO Moderate/ Severe Bleed Cumulative Incidence of MACCE 10 % 8 % 6 % 4 % 2 % 0 % 1 2 Continued Thienopyridine Placebo 2.7% vs. 5.7% P<0.001 1 5 1 8 GUSTO Moderate/ Severe Bleeding Stent Thrombosis or MI 2 Months 1 After Enrollment 10 % 8 % 6 % 4 % 2 % 0 % 1 Yeh RW et al. JAMA 2016;315:1735-49 2 2 4 2 7 1.8% vs. 1.4% P=0.26 3 0 Continued Thienopyridine Placebo 1 5 1 8 10 % 8 % 6 % 4 % 2 % 0 % 1 2 2 Months 1 After Enrollment 2 4 Continued Thienopyridine Placebo 4.9% vs. 7.6% P<0.001 1 5 2 7 1 8 2 Months 1 After Enrollment 3 0 MACCE 2 4 2 7 3 0 65

Treatment effect by DAPT Score The DAPT Score accurately identifies patients with the greatest anticipated benefit vs. harm from continuing dual antiplatelet therapy beyond 12 months among randomized patients in the DAPT Study Low DAPT Score (< 2) NNT to prevent ischemia = 153 NNH to cause bleeding 64 High DAPT Score 2 NNT to prevent ischemia = 34 NNH to cause bleeding = 272 Yeh RW et al. JAMA 2016;315:1735-49 66

Διπλη Αντιαιμοπεταλιακή αγωγη μετα απο ΟΣΣ >12 μηνες? Ποσο ενωρις?

Effect of ticagrelor on the composite of CV death, MI and stroke at 3 years by time from P2Y 12 withdrawal PEGASUS TIMI 54 P trend <0.001 Time from P2Y 12 inhibitor withdrawal to randomization 30 days n=7181 >30 days to 1 year n=6501 >1 year n=5079 3-year Kaplan-Meier rate (%) Ticagrelor Placebo HR (95% CI) P value 7.4 0.70 (0.57, 0.87) 8.0 0.75 (0.61, 0.92) 7.7 9.9 0.73 (0.61, 0.87) <0.001 8.1 0.90 (0.72, 1.12) 7.2 0.82 (0.65, 1.02) 7.6 8.7 0.86 (0.71, 1.04) 0.11 6.3 0.96 (0.73, 1,26) 6.9 1.06 (0.81, 1.38) 6.6 6.9 1.01 (0.80, 1.27) 0.96 Ticagrelor 90 mg Ticagrelor better 1.0 Placebo better Ticagrelor 60 mg Pooled Bonaca MP et al. Eur Heart J 2015:doi:10.1093/eurheartj/ehv531

Summary Post-MI patients are at high risk for recurrent ischaemic events One year of DAPT is essential in all patients after MI, unless contraindicated due to high bleeding risk Withdrawal from P2Y 12 inhibition in high-risk post MI patients is associated with heightened CV risk Longer event-free survival on ASA monotherapy is associated with lower future CV risk Prolonged and more intensive antiplatelet therapy reduces CV death and ischaemic complications in high-risk patients with prior MI Recognising the patient who will benefit from prolonged DAPT after assessing the ischaemic and bleeding risk is a matter of clinical judgement and an important aspect of the management of post-mi patients

ΕΥΧΑΡΙΣΤΩ ΠΟΛΥ